Search results
Results from the WOW.Com Content Network
Anastrozole, sold under the brand name Arimidex among others, is an antiestrogenic medication used in addition to other treatments for breast cancer. [ 6 ] [ 7 ] Specifically it is used for hormone receptor-positive breast cancer. [ 7 ]
Medication discontinuation is the ceasing of a medication treatment for a patient by either the clinician or the patient themself. [1] [2] When initiated by the clinician, it is known as deprescribing. [3] Medication discontinuation is an important medical practice that may be motivated by a number of reasons: [4] [3] Reducing polypharmacy
Women post-menopause with ‘strong family history’ of breast cancer encouraged speak to GP about drug, expert says What is Anastrozole? The breast cancer drug that can cut risk by half
Deprescribing can improve adherence, cost, and health outcomes but may have adverse drug withdrawal effects. More specifically, deprescribing is the planned and supervised process of intentionally stopping a medication or reducing its dose to improve the person's health or reduce the risk of adverse side effects. Deprescribing is usually done ...
The elimination half-life of the drug is 12,5 hours and 34-54% of the drug is excreted unchanged in the urine. [23] Anastrozole is administered orally and has a standard daily dose of 1 mg. Anastrozole has good oral bioavailability and is rapidly absorbed. It takes 2–3 hours for the drug to reach maximum serum concentration.
However, these medications do not work for everyone and can cause unpleasant side effects for some patients. For those who have recovered with the aid of antidepressants, doctors and patients may ...
Adults taking antidepressants who want to come off their medication should not go cold turkey and should instead use a “staged” approach, experts have said. ... and only when side-effects can ...
Hepatotoxicity, dermatological side effects, and abuse potential. [7] Aminopyrine: 1999 France, Thailand Risk of agranulocytosis and severe acne. [3] Amobarbital: 1980 Norway Risk of barbiturate toxicity. [3] Amoproxan: 1970 France Dermatologic and ophthalmic toxicity. [3] Anagestone acetate: 1969 Germany Animal carcinogenicity. [3] Antrafenine ...